Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients
SLE, Lupus Nephritis, SGLT2 Inhibitors
About this trial
This is an interventional prevention trial for SLE
Eligibility Criteria
Inclusion Criteria: Patients aged more than 16 year. Willing to sign informed consent. Diagnosis of SLE according to EULAR/ACR classification criteria. Renal biopsy showed lupus nephritis. Patient with eGFR > 30 ml/min/1.73m2 by cockcroft-gault equation. Exclusion Criteria: Patients with eGFR <30 ml/min per 1.73 m2. Current pregnancy or lactation. Medical history of chronic disease (CLD, cancer, severe respiratory distress, gastrointestinal tract lesions). Patients refusing to participate in the study or lost follow up. Evidence of urinary obstruction of difficulty in voiding at screening. Patients who are receiving high dose diuretics or combined ACEI, Angiotensin II receptor blockers (ARBS). Patients who have frequent hypotensive episode or SBP <100 mmHg.
Sites / Locations
- Urology and Nephrology Center
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
study group
control group
study group: will receive SGLT2i as add on drug or replace another drug according to the patient clinical situation, Dapagliflozin 10 mg will be used once daily with or without food for one ye
Control group: will receive placebo as add on drug once daily with or without food for one year.